Innovation Pharmaceuticals

Innovation Pharmaceuticals is a publicly traded biopharmaceutical company advancing with dermatology, oncology, anti-inflammatory and antibiotic applications.

[Innovation Pharmaceuticals @InnovationPhar5]

Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of #Brilacidin for COVID-19 https://t.co/D1mwr3EjWg #SARSCoV2 @US_FDA @PharmaReview

[Innovation Pharmaceuticals @InnovationPhar5]

https://t.co/eA4XEMzdJ9 #Brilacidin #DefensinMimetic @NIH @CDCDirector @PharmaReview @EMA_News @FDACDERDirector

[Innovation Pharmaceuticals @InnovationPhar5]

Innovation updates on mid-stage Brilacidin COVID-19 trial #brilacidin #SARS_CoV_2 #therapeutic https://t.co/WahHun4nki

[Innovation Pharmaceuticals @InnovationPhar5]

https://t.co/D1mwr3EjWg There will be a long-term need and we're looking to address this with #Brilacidin. @NIH @CDCDirector @PharmaReview @DrEricDing @DrWoodcockFDA

[Innovation Pharmaceuticals @InnovationPhar5]

https://t.co/Uk6Wu8cmnX #Brilacidin #DefensinMimetic @NIH @FDACDERDirector @PharmaReview @CDCDirector

[Innovation Pharmaceuticals @InnovationPhar5]

https://t.co/Q5vjtB6JON #SARS_CoV_2 #Brilacidin #Therapeutics #ClinicalTrials @US_FDA @PharmaReview @CDCDirector

[Innovation Pharmaceuticals @InnovationPhar5]

@ScottGottliebMD perhaps some better therapeutic options would help as well? https://t.co/LLgrCfswbz

[Innovation Pharmaceuticals @InnovationPhar5]

@NIHDirector https://t.co/LLgrCfswbz there are others coming... We look forward to your input.

[Innovation Pharmaceuticals @InnovationPhar5]

#Brilacidin, #DefensinMimetic #Therapeutic #SARS_CoV_2, # PeerReview @business @MSNBC @maddow @NIHDirector @NIH @PharmaReview Hoping to contribute to health and wellness for the world. https://t.co/LLgrCfswbz

[Innovation Pharmaceuticals @InnovationPhar5]

Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week https://t.co/qkZkaoaKfx #SARS_CoV_2 #Therapeutic @NIHDirector @CDCDirector @PharmaReview

[Innovation Pharmaceuticals @InnovationPhar5]

@JohnCendpts We need effective and safe therapeutics at this stage... #brilacidin #defensinMimetic and the #FastTrackDesignation doesn’t hurt either... stay tuned

[Innovation Pharmaceuticals @InnovationPhar5]

Rogue antibodies could be driving severe COVID-19 https://t.co/Uad9ocONFB #nature #SARS_CoV_2

[Innovation Pharmaceuticals @InnovationPhar5]

#SARS_CoV_2 #covid19 #update coronavirus variants. https://t.co/jnlZRrqaFC

[Innovation Pharmaceuticals @InnovationPhar5]

Why you really don’t want #covid to begin with... #WearAMask
#therapeutics #brilacidin #defensinMimetic

https://t.co/Z7oRFTqu2k

[Innovation Pharmaceuticals @InnovationPhar5]

Taking a Closer Look at COVID-19’s Effects on the Brain – NIH Director's Blog. Interesting study here, and a further highlight for the need for #Brilacidin to progress in the fight against #SARS_CoV-2 https://t.co/6ruXqln9ei

[Innovation Pharmaceuticals @InnovationPhar5]

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation https://t.co/Z0NwKXHwPF #SARS_CoV_2 #AntiViral #DefensinMimetic @bmsnews @NIHDirector @PharmaReview @CDCgov

[Innovation Pharmaceuticals @InnovationPhar5]

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ #Brilacidin for Treating COVID-19 https://t.co/8nF6EVnHME @NIHDirector @JohnCendpts @washingtonpost @ScottGottliebMD @BARDA @maddow @PharmaReview

[Innovation Pharmaceuticals @InnovationPhar5]

In related news, requisite documentation has been filed with the appropriate regulatory agencies, including an Investigational New Drug application (IND) with the FDA, for the conduct of a multinational Phase 2 clinical trial of Brilacidin in patients hospitalized with COVID-19.

[Innovation Pharmaceuticals @InnovationPhar5]

Innovation Pharmaceuticals- advancing #Brilacidin as a next-generation broad-spectrum #antiviral for the treatment of common colds and deadly #coronavirus infections. https://t.co/TtyftghGV6 #SARS_CoV_2 #COVID19 #DefensinMimetic @DrAnthonyF @US_FDA @NIHDirector @BARDA

[Innovation Pharmaceuticals @InnovationPhar5]

Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study #brilacidin #defensinMimetic ⁦@NIHDirector⁩ ⁦@BARDA⁩ ⁦@PharmaReview⁩ ⁦@EU_Commission⁩ ⁦@US_FDA⁩ ⁦@DrAnthonyF⁩ https://t.co/R5FziLsyqK